News

Ideas That Generate Results

Flu is a respiratory illness which is caused by the influenza virus that affects the nose, throat and lungs. Some of the symptoms of this illness are fever, cough, cold, sore throat, muscle pain, headache and fatigue. Flu is primarily transmitted from person-to-person through coughing and sneezing. It is commonly treated with the help of antiviral agents such as Amantadine, Rimantadine, Zanamivir, and Oseltamivir. Apart from this therapeutic option, influenza vaccines are also administered for the prevention of this illness.
 
According to RNCOS report entitled, “Global Influenza Vaccine Market Outlook 2022”, the influenza vaccines have gained a lot of popularity in recent years due to frequent life threatening influenza outbreaks. The market for such vaccines is being driven by increasing awareness about influenza and its treatment options, growing healthcare expenditure, rising competition, increasing disposable income and huge government support.
 
Furthermore, the increasing collaborations among pharmaceutical companies and research institutes for the development of influenza vaccines are also pushing the growth of global influenza vaccine market. For instance, Sanofi Pasteur collaborated with researchers at the University of Georgia to develop a vaccine that protects against multiple strains of both seasonal and pandemic H1N1 influenza in mouse models. The vaccine is being developed by using a “Computationally Optimized Broadly Reactive Antigen”, or COBRA , technique, which will not only protect against multiple different strains of H1N1 virus at once but will also protect against many strains of seasonal influenza over several years.
 
Moreover, collaboration between vaccine and vaccine delivery companies is also an emerging trend in the influenza vaccine market. Vaccine manufacturing companies are entering into contracts with drug delivery system manufactures to make complementary products, which cannot be used without each other. For example, bioCSL, selling its influenza vaccine under the brand name Seqirus, has collaborated with PharmaJet to deliver influenza virus vaccine to people through jet injectors rather than traditional needle injections. The USFDA approved use of PharmaJet Stratis 0.5ml Needle-free Jet Injector for delivery of AFLURIA vaccine in individuals between 18-64 years in the US. Vaccination using the jet injector method provides similar level of immune protection as flu vaccine administered via traditional flu shot.
 
For FREE SAMPLE of this report visit: http://rncos.viewpage.co/Global-Influenza-Vaccine-Market-Outlook-2022
 
Check Related REPORTS on: http://www.rncos.com/Healthcare_Industry.htm
 
ABOUT RNCOS
 
RNCOS is a leading industry research and consultancy firm incorporated in 2002. As a pioneer in syndicate market research, our vision is to be a global leader in the industry research space by providing research reports and actionable insights to companies across a range of industries such as Healthcare, IT and Telecom and Retail etc. We offer comprehensive industry research studies, bespoke research and consultancy services to Fortune 1000, Trade associations, and Government agencies worldwide.